ar15512
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
6
Phase 4
0
Earliest trial started Nov 10, 2020 (NCT04498182)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06660290 | Phase 3 | Jan 31, 2025 | Alcon |
| NCT06544707 | Phase 3 | Oct 15, 2024 | Alcon |
| NCT06544694 | Phase 3 | Oct 8, 2024 | Alcon |
| NCT05493111 | Phase 3 | Nov 1, 2022 | Aerie Pharmaceuticals |
| NCT05360966 | Phase 3 | Jul 18, 2022 | Aerie Pharmaceuticals |
| NCT05285644 | Phase 3 | May 9, 2022 | Aerie Pharmaceuticals |
| NCT05497479 | Phase 1 | Dec 9, 2021 | Aerie Pharmaceuticals |
| NCT04498182 | Phase 2 | Nov 10, 2020 | Aerie Pharmaceuticals |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aerie Pharmaceuticals | For profit | 5 | 5 | 3 | 2020 |
| Alcon | For profit | 3 | 3 | 1 | 2024 |
2 organizations
Page 1 / 1